Neuronetics Inc. Common Stock (STIM)

FairStock Score: 47/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Neuronetics sells the NeuroStar Advanced Therapy System, a non-invasive, office-based transcranial magnetic stimulation treatment for major depressive disorder. That is a real clinical product, but as a value investor I ask whether the enterprise earns money and whether it has durable protection. The filed figures show fiscal Q2 2026, the quarter ended 2026-06-30, revenue of $41.6 million and a net loss of $3.4 million, or diluted EPS of -$0.05. A year earlier, in fiscal Q2 2025, the quarter ended 2025-06-30, revenue was $38.1 million and the net loss was $10.1 million, or diluted EPS of -$0.15. So revenue grew and the loss narrowed. For FY2025, the year ended 2025-12-31, revenue was $149.2 million and net loss was $39.0 million; FY2024, ended 2024-12-31, had revenue of $74.9 million and a net loss of $43.7 million. The top line has advanced, but profits remain absent.

In plain English: Neuronetics makes a non-invasive, office-based brain stimulation treatment for major depression. The business is growing revenue and its losses have narrowed recently, but it still loses money, burns cash, and carries high debt. At $1.99, the price looks expensive relative to its accounting value and current losses, so it depends on future profits that have not yet appeared.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer